Citations

Showing 10 of 108119 citations.

Prevalence of sleep disorders in Parkinson’s disease patients in Ethiopia
Melka, Dereje , Tafesse, Abenet , Bower, James H., Assefa, Demeke

Mayo Clinic

No container title available | March 20, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.442/v2 Get It

Abstract Background: Non motor symptoms (NMS) of Parkinson’s disease (PD) are common and can be more disabling than motor symptoms.Sleep disorders can be seen in up to 98% of patients with Parkinson disease. Poor sleep quality has been associated with poverty and race, and yet there has been no prior report on sleep disorders in those with PD living in sub Saharan Africa. We wished to document the prevalence of sleep disorders in PD patients in Ethiopia. Methods: We conducted a cross-sectional point prevalence study from July 1 to October 30, 2015 of all patients attending the neurology outpatient department in Tikur Anbessa and Zewuditu Memorial Hospitals, Addis Ababa, Ethiopia. Demographic data, clinical history and physical examination findings were collected from participants using a structured questionnaire. We used the Parkinson’s disease sleep scale version two (PDSS-2) and Epworth Sleepiness Scale (ESS) to assess the sleep symptoms. Results: Of the 155 patients surveyed, all patients reported some sleep problem. Over 43.9% of patients had a PDSS score > 18. Presence of previous history of sleep disturbance before PD motor symptoms (OR 3.54; 95% CI 1.61-7.76, p=0.001) and unemployment (OR 2.27; 95% CI 1.07-4.79, p=0.023) associated with a high PDSS-2 score. The median score of ESS was 9 (IQR = 5-12), with 77/155 (49.7%) of the patients having possible or definite excessive daytime somnolence. Conclusions: In Ethiopian PD patients, the prevalence of those with severe sleep disorders is the highest reported to date. The prevalence of possible/definite EDS is amongst the highest in the world. Further investigation into whether poverty or race explains this finding is needed.
Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Tempero, Margaret A. , Malafa, Mokenge P. , Chiorean, E Gabriela, Czito, Brian G. , Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Wolpin, Brian M. , Al-Hawary, Mahmoud, Asbun, Horacio, Behrman, Stephen W. , Benson, Al B. , Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Ko, Andrew H. , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, Nakakura, Eric K. , O'Reilly, Eileen M, Obando, Jorge, Reddy, Sushanth, Thayer, Sarah P. , Wolff, Robert A. , Burns, Jennifer L, Zuccarino-Catania, Griselda, LoConte, Noelle K. , Chung, Vincent , Cardin, Dana B. , O’Reilly, Eileen M. , Fountzilas, Christos , Cha, Charles , Cardin, Dana B , LoConte, Noelle , O'Reilly, Eileen M , Chung, Vincent , Chiorean, E Gabriela, Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Al-Hawary, Mahmoud, Asbun, Horacio, Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Hawkins, William G , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, O'Reilly, Eileen M, Reddy, Sushanth, Burns, Jennifer L, Zuccarino-Catania, Griselda

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 202-210

10.6004/jnccn.2019.0014 | PMID 30865919 Get It

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Hoffner, Brianna, Lunning, Matthew A. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Wahidi, Momen M. , Johnson-Chilla, Alyse, Scavone, Jillian L., Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Hoimes, Christopher , Lacouture, Mario E. , Locke, Frederick L. , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 255-289

10.6004/jnccn.2019.0013 | PMID 30865922 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org .
Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA
Wijarnpreecha, Karn , Kim, Donghee , Raymond, Pascale, Scribani, Melissa , Wijarnpreecha, Karn , Kim, Donghee , Ahmed, Aijaz

Mayo Clinic

European Journal of Gastroenterology & Hepatology | March 20, 2019 | Volume: 31 | Issue: 9 | Pages: 1121-1128

10.1097/meg.0000000000001397 | PMID 30888971 Get It

Background and aim Nonalcoholic fatty liver disease (NAFLD) may be associated with sarcopenia. This study aims to determine whether sarcopenia is independently associated with NAFLD and advanced fibrosis. Participants and methods Cross-sectional data from 11 325 participants in the third National Health and Nutrition Examination Survey were analyzed. NAFLD was defined as the presence of hepatic steatosis from the ultrasound. Sarcopenia was defined as the skeletal muscle index. Results NAFLD was more common in participants with sarcopenia than in those without (46.7 vs. 27.5%). Univariate analysis showed that sarcopenia was associated with NAFLD [odds ratio (OR): 2.31; 95% confidence interval (CI): 2.01–2.64], which remained significant after adjustment for age, sex, ethnicity, metabolic risk factors (OR: 1.24; 95% CI: 1.03–1.48). This finding persisted after adjustment for C-reactive protein as a marker of chronic inflammation. NAFLD-associated advanced fibrosis was more common in participants with sarcopenia than in those without (7.8 vs. 1.6%). Sarcopenia was associated with NAFLD-associated advanced fibrosis independent of metabolic risk factors (OR: 1.79; 95% CI: 1.18–2.72). Conclusion Sarcopenia was independently associated with increased odds of NAFLD and NAFLD-associated advanced fibrosis independent of well-defined risk factors. Interventions to strengthen muscle mass may reduce the burden of NAFLD and advanced fibrosis.
Senescence in the lung: is this getting old?
Morty, Rory E. , Prakash, Y. S. , Prakash, Y S

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | March 20, 2019 | Volume: 316 | Issue: 5 | Pages: L822-L825

10.1152/ajplung.00081.2019 | PMID 30892079 Get It

In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy
Endo, Hironobu , Shimada, Hitoshi , Ono, Maiko , Koga, Shunsuke , Kitamura, Soichiro , Niwa, Fumitoshi , Hirano, Shigeki , Kimura, Yasuyuki , Ichise, Masanori , Shinotoh, Hitoshi , Zhang, Ming Rong , Kuwabara, Satoshi , Suhara, Tetsuya , Higuchi, Makoto , Koga, Shunsuke , Sahara, Naruhiko , Dickson, Dennis W. , Toda, Tatsushi , Kuwabara, Satoshi

Mayo Clinic

Movement Disorders | March 20, 2019 | Volume: 34 | Issue: 5 | Pages: 744-754

10.1002/mds.27643 | PMID 30892739 Get It

AbstractBackground[11C]pyridinyl‐butadienyl‐benzothiazole 3 is a PET imaging agent designed for capturing pathological tau aggregates in diverse neurodegenerative disorders, and would be of clinical utility for neuropathological investigations of PSP.ObjectivesTo explore the usefulness of [11C]pyridinyl‐butadienyl‐benzothiazole 3/PET in assessing characteristic distributions of tau pathologies and their association with clinical symptoms in the brains of living PSP patients.MethodsWe assessed 13 PSP patients and 13 age‐matched healthy control subjects. Individuals negative for amyloid β PET with [11C]Pittsburgh compound B underwent clinical scoring, MR scans, and [11C]pyridinyl‐butadienyl‐benzothiazole 3/PET.ResultsThere were significant differences in binding potential for [11C]pyridinyl‐butadienyl‐benzothiazole 3 between PSP patients and healthy control subjects (P = 0.02). PSP patients exhibited greater radioligand retention than healthy control subjects in multiple brain regions, including frontoparietal white matter, parietal gray matter, globus pallidus, STN, red nucleus, and cerebellar dentate nucleus. [11C]pyridinyl‐butadienyl‐benzothiazole 3 deposition in frontoparietal white matter, but not gray matter, was correlated with general severity of parkinsonian and PSP symptoms, whereas both gray matter and white matter [11C]pyridinyl‐butadienyl‐benzothiazole 3 accumulations in the frontoparietal cortices were associated with nonverbal cognitive impairments. Autoradiographic and fluorescence labeling with pyridinyl‐butadienyl‐benzothiazole 3 was observed in gray matter and white matter of PSP motor cortex tissues.ConclusionsOur findings support the in vivo detectability of tau fibrils characteristic of PSP by [11C]pyridinyl‐butadienyl‐benzothiazole 3/PET, and imply distinct and synergistic contributions of gray matter and white matte tau pathologies to clinical symptoms. [11C]pyridinyl‐butadienyl‐benzothiazole 3/PET potentially provides a neuroimaging‐based index for the evolution of PSP tau pathologies promoting the deterioration of motor and cognitive functions. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Repeatability and reproducibility of 3D MR fingerprinting relaxometry measurements in normal breast tissue
Panda, Ananya , Chen, Yong , Ropella‐Panagis, Kathleen, Ghodasara, Satyam , Stopchinski, Marcie, Seyfried, Nicole, Seiberlich, Nicole , Griswold, Mark A. , Gulani, Vikas , Wright, Katherine

Mayo Clinic

Journal of Magnetic Resonance Imaging | March 20, 2019 | Volume: 50 | Issue: 4 | Pages: 1133-1143

10.1002/jmri.26717 | PMID 30892807 Get It

BackgroundThe 3D breast magnetic resonance fingerprinting (MRF) technique enables T1 and T2 mapping in breast tissues. Combined repeatability and reproducibility studies on breast T1 and T2 relaxometry are lacking.PurposeTo assess test–retest and two‐visit repeatability and interscanner reproducibility of the 3D breast MRF technique in a single‐institution setting.Study TypeProspective.SubjectsEighteen women (median age 29 years, range, 22–33 years) underwent Visit 1 scans on scanner 1. Ten of these women underwent test–retest scan repositioning after a 10‐minute interval. Thirteen women had Visit 2 scans within 7–15 days in same menstrual cycle. The remaining five women had Visit 2 scans in the same menstrual phase in next menstrual cycle. Five women were also scanned on scanner 2 at both visits for interscanner reproducibility.Field Strength/SequenceTwo 3T MR scanners with the 3D breast MRF technique.AssessmentT1 and T2 MRF maps of both breasts.Statistical TestsMean T1 and T2 values for normal fibroglandular tissues were quantified at all scans. For variability, between and within‐subjects coefficients of variation (bCV and wCV, respectively) were assessed. Repeatability was assessed with Bland–Altman analysis and coefficient of repeatability (CR). Reproducibility was assessed with interscanner coefficient of variation (CoV) and Wilcoxon signed‐rank test.ResultsThe bCV at test–retest scans was 9–12% for T1, 7–17% for T2, wCV was <4% for T1, and <7% for T2. For two visits in same menstrual cycle, bCV was 10–15% for T1, 13–17% for T2, wCV was <7% for T1 and <5% for T2. For two visits in the same menstrual phase, bCV was 6–14% for T1, 15–18% for T2, wCV was <7% for T1, and <9% for T2. For test–retest scans, CR for T1 and T2 were 130 msec and 11 msec. For two visit scans, CR was <290 msec for T1 and 10–14 msec for T2. Interscanner CoV was 3.3–3.6% for T1 and 5.1–6.6% for T2, with no differences between interscanner measurements (P = 1.00 for T1, P = 0.344 for T2).Data Conclusion3D breast MRF measurements are repeatable across scan timings and scanners and may be useful in clinical applications in breast imaging.Level of Evidence: 2Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2019;50:1133–1143.
Image‐based modeling of blood flow in cerebral aneurysms treated with intrasaccular flow diverting devices
Mut, Fernando , Chung, Bong Jae , Chudyk, Jorge , Lylyk, Pedro , Kadirvel, Ramanathan , Kallmes, David F. , Cebral, Juan R. , Cebral, Juan R

Mayo Clinic

International Journal for Numerical Methods in Biomedical Engineering | March 20, 2019 | Volume: 35 | Issue: 6 | Pages: No page available

10.1002/cnm.3202 | PMID 30891958 Get It

AbstractModeling the flow dynamics in cerebral aneurysms after the implantation of intrasaccular devices is important for understanding the relationship between flow conditions created immediately posttreatment and the subsequent outcomes. This information, ideally available a priori based on computational modeling prior to implantation, is valuable to identify which aneurysms will occlude immediately and which aneurysms will likely remain patent and would benefit from a different procedure or device.In this report, a methodology for modeling the hemodynamics in intracranial aneurysms treated with intrasaccular flow diverting devices is described. This approach combines an image‐guided, virtual device deployment within patient‐specific vascular models with an immersed boundary method on adaptive unstructured grids. A partial mesh refinement strategy that reduces the number of mesh elements near the aneurysm dome where the flow conditions are largely stagnant was compared with the full refinement strategy that refines the mesh everywhere around the device wires.The results indicate that using the partial mesh refinement approach is adequate for analyzing the posttreatment hemodynamics, at a reduced computational cost. The results obtained on a series of four cerebral aneurysms treated with different intrasaccular devices were in good qualitative agreement with angiographic observations.Promising results were obtained relating posttreatment flow conditions and outcomes of treatments with intrasaccular devices, which need to be confirmed on larger series.
Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter‐Defibrillator Therapies
Hajduk, Alexandra M. , Gurwitz, Jerry H. , Tabada, Grace H., Masoudi, Frederick A. , Magid, David J. , Greenlee, Robert T. , Sung, Sue Hee, Liu, Taylor I. , Smith, David H. , Fiocchi, Frances, Gill, Thomas M. , Gupta, Nigel, Peterson, Pamela N., Schuger, Claudio , Vidaillet, Humberto, Hammill, Stephen C., Allore, Heather , Go, Alan S. , Gill, Thomas M , Cassidy‐Bushrow, Andrea E. , Liu, Taylor , Reynolds, Kristi , Goldberg, Robert Joel , Peterson, Pamela N.

Mayo Clinic

Journal of the American Geriatrics Society | March 20, 2019 | Volume: 67 | Issue: 7 | Pages: 1370-1378

10.1111/jgs.15839 | PMID 30892695 Get It

OBJECTIVE To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies. DESIGN Retrospective cohort study. SETTING Seven US healthcare delivery systems. PARTICIPANTS Adults with left ventricular systolic dysfunction receiving an implantable cardioverter‐defibrillator (ICD) for primary prevention. MEASUREMENTS Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0‐3, 4‐5, 6‐7 and 8‐16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy. RESULTS Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4‐8), with 98% having at least two comorbidities. During a mean 2.2 years of follow‐up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14‐3.31] for 4‐5 comorbidities; HR = 2.25 [95% CI = 1.25‐4.05] for 6‐7 comorbidities; and HR = 2.91 [95% CI = 1.54‐5.50] for 8‐16 comorbidities). Participants with 8‐16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43‐3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67‐6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07‐2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies. CONCLUSIONS In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.
Single-Cell RNA-Sequencing and Optical Electrophysiology of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Discordance Between Cardiac Subtype-Associated Gene Expression Patterns and Electrophysiological Phenotypes
Biendarra‐Tiegs, Sherri M., Ye, Dan , Brandt, Emma B. , Ackerman, Michael J. , Li, Xing , Nelson, Timothy J.

Mayo Clinic

Stem Cells and Development | March 20, 2019 | Volume: 28 | Issue: 10 | Pages: 659-673

10.1089/scd.2019.0030 | PMID 30892143 Get It

The ability to accurately phenotype cells differentiated from human induced pluripotent stem cells (hiPSCs) is essential for their application in modeling developmental and disease processes, yet also poses a particular challenge without the context of anatomical location. Our specific objective was to determine if single-cell gene expression was sufficient to predict the electrophysiology of iPSC-derived cardiac lineages, to evaluate the concordance between molecular and functional surrogate markers. To this end, we used the genetically encoded voltage indicator ArcLight to profile hundreds of hiPSC-derived cardiomyocytes (hiPSC-CMs), thus identifying patterns of electrophysiological maturation and increased prevalence of cells with atrial-like action potentials (APs) between days 11 and 42 of differentiation. To profile expression patterns of cardiomyocyte subtype-associated genes, single-cell RNA-seq was performed at days 12 and 40 after the populations were fully characterized with the high-throughput ArcLight platform. Although we could detect global gene expression changes supporting progressive differentiation, individual cellular expression patterns alone were not able to delineate the individual cardiomyocytes into atrial, ventricular, or nodal subtypes as functionally documented by electrophysiology measurements. Furthermore, our efforts to understand the distinct electrophysiological properties associated with day 12 versus day 40 hiPSC-CMs revealed that ion channel regulators SLMAP , FGF12 , and FHL1 were the most significantly increased genes at day 40, categorized by electrophysiology-related gene functions. Notably, FHL1 knockdown during differentiation was sufficient to significantly modulate APs toward ventricular-like electrophysiology. Thus, our results establish the inability of subtype-associated gene expression patterns to specifically categorize hiPSC-derived cells according to their functional electrophysiology, and yet, altered FHL1 expression is able to redirect electrophysiological maturation of these developing cells. Therefore, noncanonical gene expression patterns of cardiac maturation may be sufficient to direct functional maturation of cardiomyocytes, with canonical gene expression patterns being insufficient to temporally define cardiac subtypes of in vitro differentiation.